Lilly Misses Profit Projects As Sales Of Diabetes Drug Slow
Lilly Misses Profit Projects As Sales Of Diabetes Drug Slow
Eli Lilly and Co. is reporting thirdquarter net income of $1.21 billion.

INDIANAPOLIS: Eli Lilly and Co. is reporting third-quarter net income of $1.21 billion.

On a per-share basis, the Indianapolis company said it had profit of $1.33. Earnings, adjusted for asset impairment costs, were $1.54 per share. That’s far short of the per-share earnings of $1.76 that Wall Street was looking for, according to a survey of analysts by Zacks Investment Research.

Revenue was $5.74 billion.

Lilly expects full-year earnings in the range of $7.20 to $7.40 per share, with revenue in the range of $23.7 billion to $24.2 billion.

Lilly shares have risen 8% since the beginning of the year, while the Standard & Poors 500 index has increased slightly more than 5%. The stock has risen 32% in the last 12 months.

_____

A portion of this story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on LLY at https://www.zacks.com/ap/LLY

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Read all the Latest News and Breaking News here

What's your reaction?

Comments

https://umorina.info/assets/images/user-avatar-s.jpg

0 comment

Write the first comment for this!